Intra-Cellular Therapies' (NASDAQ:ITCI) stock could have used a little financial therapy on Tuesday. The neurologic drugs-focused biotech saw its shares decline by over 14% on the day, following news that it is entering a new round of capital-raising.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,